摘要
目的:探讨天麻钩藤饮对原发性高血压(肝阳上亢型)患者血压和血浆内皮素的影响,为临床高血压患者的治疗及康复措施介入提供有力的理论依据。方法:所有病例均为中南大学湘雅医院2001-09/2002-09住院或门诊患者,采用随机分组法将患者分为2组,天麻钩藤饮组(52例),男41例,女11例,平均年龄(55±4)岁。对照组(50例),男41例,女9例,平均年龄(54±5)岁。纳入标准:符合1999年世界卫生组织修订的高血压诊断分级标准及肝阳上亢症辨证标准。排除标准:除外冠心病、脑卒中、肾功能不全、Ⅲ级高血压的患者。天麻钩藤饮组以天麻钩藤饮治疗,对照组以尼群地平片治疗,两组均连续治疗4周。两组治疗4周后,观察治疗前后血压的改变及血浆内皮素的变化。结果:天麻钩藤饮组血压明显降低(t=2.400,P<0.05),对照组血压明显降低(t=2.210,P<0.05),天麻钩藤饮组治疗前内皮素水平犤(87.96±13.57)ng/L犦明显高于治疗后犤(56.21±14.00)ng/L犦(t=2.651,P<0.01)。结论:天麻钩藤饮能显著降低高血压患者血压,其作用机制可能是通过降低内皮素而发挥作用。
AIM:To investigate the effects of tianma gouteng decoction to the blood pressure and plasma endothelin of patients with primary hypertension in order to provide theoretic basis for treatment and rehabilitation. METHODS:All the cases were chosen from hospitalized patients or outpatients of Xiangya Hospital of Central South University during September 2001 to September 2002.They were randomly divided into two groups:52 cases in tianma gouteng group with 41 males and 11 females,mean age was(55±4) years old.Selecting criteria:Meet the diagnostic classification standard of WHO edited in 1999 and the differentiation standards of hyperactivity of liver yang.Exclusive criteria:Patients with coronary heart disease,cerebral apoplexy,renal insufficiency and III level hypertension were excluded.Tianma gouteng group was administrated with tianma gouteng decoction while control group was provided nitrendipine for 4 weeks.The changes of blood pressure and plasma endothelin were observed after 4 weeks treatment to both groups. RESULTS:The blood pressure of both tianma gouteng group(t=2.400,P< 0.05)and control group(t=2.210,P< 0.05) was remarkably reduced.The plasma endothelin level before treatment[(87.96±13.57)ng/L] was much higher than that after treatment [(56.21±14.00)ng/L] in tianma gouteng group(t=2.651,P< 0.01). CONCLUSION:Tianma gouteng can greatly reduce the blood pressure of patients with hypertension.The possible mechanism of it is due to the decrease of endothelin level.
出处
《中国临床康复》
CSCD
2004年第27期5992-5993,共2页
Chinese Journal of Clinical Rehabilitation
基金
湖南省卫生厅中医药科研基金资助(202060)~~
